基於NO / GSNO的中風治療神經再生策略(An NO/GSNO-based Neuroregeneration Strategy for Stroke Therapy)



中風的發病率和死亡率顯著地與受損腦的神經再生能力的受限相關。除了在組織僅提供短暫的治療窗口(~3小時)的組織纖溶酶原激活劑(tPA)的急性期溶栓治療之外,,無法進行理想的中風治療的主要原因是,對神經再生機制和慢性期功能恢復的相對理解度缺乏。

然而,已經顯示許多藥物療法,包括S-亞硝基穀胱甘肽(GSNO),在短暫性腦缺血再灌注(IR)和永久性缺血的動物模型中,提供了針對急性疾病的神經的保護作用。 

GSNO在刺激疾病的慢性期神經再生相關因子加速恢復也是有效的。

在這篇簡短的綜述中,我們評估了實驗性中風後支持實驗性中風後外源性GSNO藥的證據 ,因為通過穩定HIF-1α/ VEGF途徑作為一種手段,對於刺激神經再生和功能恢復有幫助。



Stroke is associated with significant morbidity and mortality due to the limited neuroregeneration capacity of the injured brain. Other than thrombolysis in the acute phase of the disease by tissue plasminogen activator (tPA), which offers only a short window of treatment (~3 hours), an ideal stroke therapy is not available mainly because of limited understanding of the mechanisms of neuroregeneration and functional recovery in the chronic phase. Yet many drug therapies, including S-nitrosoglutathione (GSNO), have been shown to provide neuroprotection against acute disease in animal models of transient cerebral ischemia reperfusion (IR) and permanent ischemia. GSNO was also effective in stimulating neuroregeneration-related factors in the chronic phase of the disease. In this short review, we assess the evidence supporting exogenous administration of GSNO after experimental stroke as a means to stimulate neuroregeneration and aid in functional recovery via stabilization of the HIF-1α/VEGF pathway.

原文連接

論文下載

#GSNO #天然誓約
Powered by Blogger.